About this trial
The study will aim to evaluate the effects of consuming freeze-dried aronia berries as an adjunct to medical treatment in patients with chronic obstructive pulmonary disease (COPD), focusing on anti-inflammatory, respiratory, and biochemical parameters.
It will be conducted at a research hospital in Istanbul, involving 50 participants aged 50-80 diagnosed with COPD. Participants will be randomly assigned to two groups: the aronia group (AG, n=25) and the placebo group (PG, n=25). The AG will receive 30 g of freeze-dried aronia powder daily, while the PG will receive 30 g of placebo powder, both for a duration of 8 weeks. Baseline demographic data will be collected through face-to-face interviews, while biochemical, respiratory, anthropometric, and body composition parameters will be assessed both before and after the intervention. Dietary intake records will also be collected and analyzed.
Eligibility criteria
Qualifiers
Aged 50-80 years
Diagnosed with COPD
Not following a vegetarian or vegan diet
Willing to consume the provided aronia berry (black chokeberry)
Disqualifiers
Presence of associated chronic inflammatory/rheumatic diseases
Chronic infections that may create a prothrombotic state
Chronic kidney disease (CKD)
Malignancy
Trial design
Treatments tested in this trial
- Black chokeberry (Aronia melanocarpa)
- Placebo powder